A phase 1 randomized controlled trial has found an Ebola virus disease (EVD) vaccine, developed in Canada, was well-tolerated with no safety concerns, and high antibodies were present in participants 6 months after immunization. ...
105
0
Within seven days of vaccination, a blood test early after vaccination can predict whether vaccines based on living, modified viruses have had the desired effect. This is one of the results of a new study from a large European ...
0
0
Viruses and their hosts are in a eternal game of one-upmanship. If a host cell evolves a way to stop a virus from spreading, the virus will look for a new path. And so on and so forth.
20
0
Forty years after emerging in what is today the Democratic Republic of Congo, the Ebola virus may finally have met its match in a vaccine which could be "up to 100 percent effective", according to its makers.
0
0
Two investigational vaccines designed to protect against Ebola virus disease were well-tolerated and induced an immune response among 1,000 vaccinated participants in the Phase 2 randomized, placebo-controlled clinical trial ...
0
0
The recent Ebola outbreak in West Africa has claimed more than 11,300 lives and starkly revealed the lack of effective options for treating or preventing the disease. Progress has been made on developing vaccines, but there ...
23
0
National Institutes of Health (NIH) scientists report that a single dose of an experimental Ebola virus (EBOV) vaccine completely protects cynomolgus macaques against the current EBOV outbreak strain, EBOV-Makona, when given ...
59
0
A live vaccine based on the "Vesicular Stomatitis Virus" (VSV) has yielded highly promising results for the rapid development of an effective vaccine against the Ebola virus. This vaccine would only need to be injected once ...
3
0
(Medical Xpress)—A brain-computer-interphase that is optogenetically-enabled is one of the most fantastic technologies we might envision today. It is likely that its full power could only be realized under the guidance ...
Human testing of a second investigational Ebola vaccine candidate is under way at the National Institutes of Health's Clinical Center in Bethesda, Maryland.
0
0
Subscribe to rss feed
